[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  Genmab A/S Genmab's DARZALEX sales are up, and the company is hiring. Positive news from partners and strong Q2 sales are driving investor interest. ### About Genmab A/S Genmab A/S is a biotechnology company focused on antibody therapeutics. ### Insights [#](/topic/$gmabco/insights) - Genmab A/S sentiment is up XXXXX% from the previous week. - Genmab A/S engagements is up XXXXX% from the previous week. - Genmab A/S posts created is up XX% from the previous week. ### Price: $ [#](/topic/$gmabco/close) ---  [Price 24-Hour Chart Data](/topic/$gmabco/time-series/close.tsv) The price is experiencing positive momentum driven by positive trial results, investor interest, and expansion, as indicated by high engagement, creator activity, and mentions, suggesting a continued upward trend. **1-Year High**: $XXXXX on 2024-08-01 **1-Year Low**: $XXXXXXXX on 2025-04-09 ### AltRank: undefined [#](/topic/$gmabco/alt_rank) ---  [AltRank 24-Hour Chart Data](/topic/$gmabco/time-series/alt_rank.tsv) Genmab A/S is currently AltRank #undefined based on combined combined social and market metrics **Daily Average**: XXX **1-Year High**: XXXXX on 2024-09-16 **1-Year Low**: XXX on 2025-03-03 ### Galaxy Score: XX [#](/topic/$gmabco/galaxy_score) ---  [Galaxy Score 24-Hour Chart Data](/topic/$gmabco/time-series/galaxy_score.tsv) **Current Value**: XX **Daily Average**: XX **1-Year High**: XX on 2025-03-03 **1-Year Low**: XX on 2025-07-03 ### Engagements: XXXXX [#](/topic/$gmabco/interactions) ---  [Engagements 24-Hour Chart Data](/topic/$gmabco/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXXXX **1 Week**: XXXXXX +70% **1 Month**: XXXXXX -XX% **6 Months**: XXXXXXXXX +15% **1 Year**: XXXXXXXXX +179% **1-Year High**: XXXXXXX on 2024-11-15 **1-Year Low**: X on 2024-09-02 | Social Network | X | Reddit | YouTube | TikTok | | -------------- | - | ------ | ------- | ------ | | Engagements | XXXXX | XX | XX | X | ### Mentions: XX [#](/topic/$gmabco/posts_active) ---  [Mentions 24-Hour Chart Data](/topic/$gmabco/time-series/posts_active.tsv) **Current Value**: XX **Daily Average**: XX **1 Week**: XXX +4.10% **1 Month**: XXX +4.90% **6 Months**: XXX +100% **1 Year**: XXXXX +109% **1-Year High**: XXX on 2025-07-10 **1-Year Low**: X on 2024-09-16 | Social Network | X | Reddit | YouTube | TikTok | | -------------- | - | ------ | ------- | ------ | | Mentions | XX | XX | X | X | ### Creators: XX [#](/topic/$gmabco/contributors_active) ---  [Creators 24-Hour Chart Data](/topic/$gmabco/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning Genmab A/S in the last XX hours which is up XX% from XX in the previous XX hours **Daily Average**: XX **1 Week**: XX -X% **1 Month**: XXX +1.30% **6 Months**: XXX +99% **1 Year**: XXX +56% **1-Year High**: XX on 2025-07-10 **1-Year Low**: X on 2024-09-16 ### Sentiment: XX% [#](/topic/$gmabco/sentiment) ---  [Sentiment 24-Hour Chart Data](/topic/$gmabco/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XXX% +12% **1 Month**: XX% no change **6 Months**: XX% -X% **1 Year**: XX% +1% **1-Year High**: XXX% on 2024-07-26 **1-Year Low**: XX% on 2024-08-28 **Most Supportive Themes** - **ASCO 2025:** (35%) Genmab's participation in ASCO 2025 is driving interest in antibody therapies. - **Rina-S Trial Results:** (25%) Positive data from the Rina-S trial is generating optimism. - **Patient Advocacy and Support:** (20%) Genmab's dedication to patient support is resonating with the community. **Most Critical Themes** - **Market Cap Uncertainty:** (10%) Concerns about future market performance have surfaced regarding Genmab A/S. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XXX | X% | XXXXX | XX% | XX | X% | | Reddit | X | X% | XX | X% | X | X% | | YouTube | X | X% | XX | X% | X | X% | | TikTok | X | X% | X | X% | X | X% | | | | | | | | | | Total | XXX | X% | XXXXX | XX% | XX | X% | ### Market Cap: $undefined [#](/topic/$gmabco/market_cap) ---  [Market Cap 24-Hour Chart Data](/topic/$gmabco/time-series/market_cap.tsv) **Current Value**: $undefined **Daily Average**: $XXXXXXXXXXXXXXX **1-Year High**: $XXXXXXXXXXXXXXX on 2024-08-01 **1-Year Low**: $XXXXXXXXXXXXXX on 2025-04-01 **Top assets mentioned** In the posts about Genmab A/S in the last XX hours [AbbVie Inc (ABBV)](/topic/$abbv) [Novartis AG (NVS)](/topic/novartis) [Vertex Protocol (VRTX)](/topic/$vrtx) [Eli Lilly and Company (LLY)](/topic/$lly) [ResMed Inc. (RMD)](/topic/$rmd) [Zoetis Inc (ZTS)](/topic/$zts) [Microsoft Corp. (MSFT)](/topic/microsoft) [Amgen, Inc. (AMGN)](/topic/$amgn) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Skyworks Solutions Inc (SWKS)](/topic/$swks) **Top topics mentioned** In the posts about Genmab A/S in the last XX hours [$gmab](/topic/$gmab), [stocks healthcare](/topic/stocks-healthcare), [investment](/topic/investment), [stocks](/topic/stocks), [novo](/topic/novo), [stocks technology](/topic/stocks-technology), [$gentol](/topic/$gentol), [$ipatf](/topic/$ipatf), [$abbv](/topic/$abbv), [$novcde](/topic/$novcde), [asml](/topic/asml), [$xbranest](/topic/$xbranest), [$crmd](/topic/$crmd), [denmark](/topic/denmark), [$rbrewco](/topic/$rbrewco), [$nemasw](/topic/$nemasw), [coins healthcare](/topic/coins-healthcare), [$6160hk](/topic/$6160hk), [biontech](/topic/biontech), [banking](/topic/banking), [fintech](/topic/fintech), [novartis](/topic/novartis), [$novnsw](/topic/$novnsw), [$trygco](/topic/$trygco), [corcept therapeutics](/topic/corcept-therapeutics), [$argx](/topic/$argx), [$vrtx](/topic/$vrtx), [$lly](/topic/$lly), [$rmd](/topic/$rmd), [$zts](/topic/$zts), [$wppl](/topic/$wppl), [$6758t](/topic/$6758t), [sony](/topic/sony), [lyft](/topic/lyft), [ach](/topic/ach), [$1b](/topic/$1b), [$ipav](/topic/$ipav), [$diami](/topic/$diami), [italy](/topic/italy), [germany](/topic/germany), [switzerland](/topic/switzerland), [$asmlas](/topic/$asmlas), [bali](/topic/bali), [combo](/topic/combo), [pd](/topic/pd), [danish krone](/topic/danish-krone), [told](/topic/told), [microsoft](/topic/microsoft), [abbv](/topic/abbv), [$amgn](/topic/$amgn), [eli lilly](/topic/eli-lilly), [$siede](/topic/$siede), [$siemensbo](/topic/$siemensbo), [$shlde](/topic/$shlde), [$atdto](/topic/$atdto), [$atdbto](/topic/$atdbto), [constellation](/topic/constellation), [$csuto](/topic/$csuto), [canada](/topic/canada), [dow](/topic/dow), [$tte](/topic/$tte), [$swks](/topic/$swks), [$stm](/topic/$stm), [$qrvo](/topic/$qrvo), [tak](/topic/tak), [biib biogen](/topic/biib-biogen), [$gmxay](/topic/$gmxay), [$112m](/topic/$112m), [$70m](/topic/$70m), [seed funding](/topic/seed-funding), [$18bn](/topic/$18bn), [nasdaq](/topic/nasdaq), [$jyskco](/topic/$jyskco), [sec](/topic/sec), [billions](/topic/billions), [savings](/topic/savings), [nem](/topic/nem), [$deck](/topic/$deck), [$stmnsw](/topic/$stmnsw), [$stmn](/topic/$stmn), [$4587t](/topic/$4587t), [cdx](/topic/cdx), [$googl](/topic/$googl), [australia](/topic/australia), [$adyenas](/topic/$adyenas), [netherlands](/topic/netherlands), [$bgne](/topic/$bgne), [$baynsg](/topic/$baynsg), [$8750t](/topic/$8750t), [nvda](/topic/nvda), [msft](/topic/msft), [pypl](/topic/pypl), [$now](/topic/$now), [$bonex](/topic/$bonex), [$mrk](/topic/$mrk), [$orstedco](/topic/$orstedco), [money](/topic/money), [cro](/topic/cro), [#ai](/topic/#ai), [open ai](/topic/open-ai) ### Top Social Posts [#](/topic/$gmabco/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "FDA rejects new indication for Columvi Roche Genentech $ABBV $GMAB AbbVie Genmab #Epkinly #Epcoritamab via @onclive" [@EgidiusLambrech](/creator/x/EgidiusLambrech) on [X](/post/tweet/1947207891301073191) 2025-07-21 08:11:53 UTC XXX followers, XXX engagements "#AVCT This is what $1.8Bn looked like last year: Profound Bio was a ADC startup led by Seagen veterans founded in 2018. It had two rounds of funding. Series A - $70m; Series B - $112M (February 2024) ProfoundBio was taken over two months after their series B funding in April 2024. Acquired by Genmab. Deal value: $1.8Bn. Lead asset: TOP1 ADC Rina S a drug designed to target tumors that express a protein called folate receptor alpha. Phase: completed Phase X of a Phase 1/2 study. Indications: Ovarian (and other indications which were high in FR-expression). Public results at time of take over:" [@RAH00084](/creator/x/RAH00084) on [X](/post/tweet/1947002919028449465) 2025-07-20 18:37:24 UTC 2456 followers, 7523 engagements "Now isn't this interesting I just pulled up the McCullough Foundation IRS filing. Below are their investments including: AMGEN Genmab Eli Lilly United Healthcare and none other than Pfizer. So the boards of these companies push the executives of these companies to make more profit for . The McCullough Foundation By the way they also donate to a great group of charities" [@efdavis419](/creator/x/efdavis419) on [X](/post/tweet/1946248164509675851) 2025-07-18 16:38:16 UTC XXX followers, XXX engagements "@ttt_financial @Stock_Bonvivant @krappsholidy @ball_hartwig @BcPoldi @VidarCoc @Hanseat2021 @jusifov @LeoNelissen @aktien_max @topsecretstocks @ppinvest @KielerFinanzen Positiv diese Woche zB $EVO $ASTS $VNOM Genmab Negativ: Sanlorenzo Novo" [@robmelzer11](/creator/x/robmelzer11) on [X](/post/tweet/1946113319351308466) 2025-07-18 07:42:27 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Genmab A/S
Genmab's DARZALEX sales are up, and the company is hiring. Positive news from partners and strong Q2 sales are driving investor interest.
About Genmab A/S
Genmab A/S is a biotechnology company focused on antibody therapeutics.
Insights #
- Genmab A/S sentiment is up XXXXX% from the previous week.
- Genmab A/S engagements is up XXXXX% from the previous week.
- Genmab A/S posts created is up XX% from the previous week.
Price: $ #
Price 24-Hour Chart Data
The price is experiencing positive momentum driven by positive trial results, investor interest, and expansion, as indicated by high engagement, creator activity, and mentions, suggesting a continued upward trend.
1-Year High: $XXXXX on 2024-08-01
1-Year Low: $XXXXXXXX on 2025-04-09
AltRank: undefined #
AltRank 24-Hour Chart Data
Genmab A/S is currently AltRank #undefined based on combined combined social and market metrics
Daily Average: XXX
1-Year High: XXXXX on 2024-09-16
1-Year Low: XXX on 2025-03-03
Galaxy Score: XX #
Galaxy Score 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-03-03
1-Year Low: XX on 2025-07-03
Engagements: XXXXX #
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXXXX
1 Week: XXXXXX +70%
1 Month: XXXXXX -XX%
6 Months: XXXXXXXXX +15%
1 Year: XXXXXXXXX +179%
1-Year High: XXXXXXX on 2024-11-15
1-Year Low: X on 2024-09-02
| Social Network | X | YouTube | TikTok | |
|---|---|---|---|---|
| Engagements | XXXXX | XX | XX | X |
Mentions: XX #
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XXX +4.10%
1 Month: XXX +4.90%
6 Months: XXX +100%
1 Year: XXXXX +109%
1-Year High: XXX on 2025-07-10
1-Year Low: X on 2024-09-16
| Social Network | X | YouTube | TikTok | |
|---|---|---|---|---|
| Mentions | XX | XX | X | X |
Creators: XX #
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning Genmab A/S in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XX
1 Week: XX -X%
1 Month: XXX +1.30%
6 Months: XXX +99%
1 Year: XXX +56%
1-Year High: XX on 2025-07-10
1-Year Low: X on 2024-09-16
Sentiment: XX% #
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% +12%
1 Month: XX% no change
6 Months: XX% -X%
1 Year: XX% +1%
1-Year High: XXX% on 2024-07-26
1-Year Low: XX% on 2024-08-28
Most Supportive Themes
- ASCO 2025: (35%) Genmab's participation in ASCO 2025 is driving interest in antibody therapies.
- Rina-S Trial Results: (25%) Positive data from the Rina-S trial is generating optimism.
- Patient Advocacy and Support: (20%) Genmab's dedication to patient support is resonating with the community.
Most Critical Themes
- Market Cap Uncertainty: (10%) Concerns about future market performance have surfaced regarding Genmab A/S.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXX | X% | XXXXX | XX% | XX | X% |
| X | X% | XX | X% | X | X% | |
| YouTube | X | X% | XX | X% | X | X% |
| TikTok | X | X% | X | X% | X | X% |
| Total | XXX | X% | XXXXX | XX% | XX | X% |
Market Cap: $undefined #
Market Cap 24-Hour Chart Data
Current Value: $undefined
Daily Average: $XXXXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXXXX on 2024-08-01
1-Year Low: $XXXXXXXXXXXXXX on 2025-04-01
Top assets mentioned In the posts about Genmab A/S in the last XX hours
AbbVie Inc (ABBV) Novartis AG (NVS) Vertex Protocol (VRTX) Eli Lilly and Company (LLY) ResMed Inc. (RMD) Zoetis Inc (ZTS) Microsoft Corp. (MSFT) Amgen, Inc. (AMGN) Eli Lilly and Company (LLY) Skyworks Solutions Inc (SWKS)
Top topics mentioned In the posts about Genmab A/S in the last XX hours
$gmab, stocks healthcare, investment, stocks, novo, stocks technology, $gentol, $ipatf, $abbv, $novcde, asml, $xbranest, $crmd, denmark, $rbrewco, $nemasw, coins healthcare, $6160hk, biontech, banking, fintech, novartis, $novnsw, $trygco, corcept therapeutics, $argx, $vrtx, $lly, $rmd, $zts, $wppl, $6758t, sony, lyft, ach, $1b, $ipav, $diami, italy, germany, switzerland, $asmlas, bali, combo, pd, danish krone, told, microsoft, abbv, $amgn, eli lilly, $siede, $siemensbo, $shlde, $atdto, $atdbto, constellation, $csuto, canada, dow, $tte, $swks, $stm, $qrvo, tak, biib biogen, $gmxay, $112m, $70m, seed funding, $18bn, nasdaq, $jyskco, sec, billions, savings, nem, $deck, $stmnsw, $stmn, $4587t, cdx, $googl, australia, $adyenas, netherlands, $bgne, $baynsg, $8750t, nvda, msft, pypl, $now, $bonex, $mrk, $orstedco, money, cro, #ai, open ai
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"FDA rejects new indication for Columvi Roche Genentech $ABBV $GMAB AbbVie Genmab #Epkinly #Epcoritamab via @onclive"
@EgidiusLambrech on X 2025-07-21 08:11:53 UTC XXX followers, XXX engagements
"#AVCT This is what $1.8Bn looked like last year: Profound Bio was a ADC startup led by Seagen veterans founded in 2018. It had two rounds of funding. Series A - $70m; Series B - $112M (February 2024) ProfoundBio was taken over two months after their series B funding in April 2024. Acquired by Genmab. Deal value: $1.8Bn. Lead asset: TOP1 ADC Rina S a drug designed to target tumors that express a protein called folate receptor alpha. Phase: completed Phase X of a Phase 1/2 study. Indications: Ovarian (and other indications which were high in FR-expression). Public results at time of take over:"
@RAH00084 on X 2025-07-20 18:37:24 UTC 2456 followers, 7523 engagements
"Now isn't this interesting I just pulled up the McCullough Foundation IRS filing. Below are their investments including: AMGEN Genmab Eli Lilly United Healthcare and none other than Pfizer. So the boards of these companies push the executives of these companies to make more profit for . The McCullough Foundation By the way they also donate to a great group of charities"
@efdavis419 on X 2025-07-18 16:38:16 UTC XXX followers, XXX engagements
"@ttt_financial @Stock_Bonvivant @krappsholidy @ball_hartwig @BcPoldi @VidarCoc @Hanseat2021 @jusifov @LeoNelissen @aktien_max @topsecretstocks @ppinvest @KielerFinanzen Positiv diese Woche zB $EVO $ASTS $VNOM Genmab Negativ: Sanlorenzo Novo"
@robmelzer11 on X 2025-07-18 07:42:27 UTC XXX followers, XXX engagements